FOLR1 / DR5 bispecific antibody family
Granted February 10, 2026. The earlier US 2020/0283537 publication belongs to the same family.
Innovation & intellectual property
Published patent and university technology records connected to the research.
Tumor-specific Fas epitope antibodies
UC Davis technology 33636; additional patent pending per the university listing.
Engineered HCMV-derived DR5 / CD155 biologic
UC Davis technology 33058; clinical benefit is unestablished.
BPTI-derived stable peptide
The public listing does not provide a published application number.
A patent grant, a published application and a technology disclosure have different legal meanings. Experimental technologies are not approved treatments.